Since David's death however, researchers have refined treatment options for children with SCID, and today, as scientists at Duke University Medical Center report in The Journal of Pediatrics, most of them who undergo related donor bone marrow transplants manage to grow up, go to school, and for the most part, lead pretty normal lives.
That conclusion comes from the longest and largest study to date of children with SCID treated at a single center. Led by Rebecca H. Buckley, M.D., professor of pediatrics and immunology at Duke, researchers followed for up to 26 years 110 of the 124 surviving SCID children out of the 161 who had come to Duke for bone marrow transplants. The study involved periodic questionnaires and visits to Duke for reassessment of various aspects of their lives, including immune function, growth, behavior, nutritional needs, mental, physical, and emotional well-being and any trouble with recurrent infections.
Buckley says the data clearly show that SCID infants who receive a related donor bone marrow transplant within the first 14 weeks of life are significantly more likely to survive and have fewer problems over time than those who receive transplants later in infancy or who have already developed an infection.
Buckley says the findings underscore the need for SCID testing at birth. "If we can identify children with SCID at birth, we can save more lives. When we transplant these babies prior to the onset of infections, 94 percent survive. But if they are older or if they have already developed an infection, only 71 percent will live."
There are at least 13 subtypes of SCID, but all arise from genetic mutations that are either inherited or arise in the infant. SCID is described as a rare disorder, but Buckley points out that no one really knows how often it occurs because testing for the condition at birth is not done. "Babies frequently die from infections, but no one thinks about SCID," Buckley says, "and autopsies are rarely done any more, so the death certificate simply lists 'infection' as the cause." Buckley believes SCID may actually be as prevalent as PKU, an inherited metabolic disorder that is routinely identified and treated through newborn screening.
Buckley has been advocating for over a decade about the need for routine screening for SCID in newborns. So far, the only states to perform it are Wisconsin and Massachusetts, which are conducting pilot studies.
In the Duke study, 77 percent of the children survived and 86 percent of those were considered healthy by their parents, says Buckley. Still, growing up with a corrected immune system is not always a sunny experience. Investigators found that 58 percent of the children needed periodic antibody therapy because of inadequate B cell function, and about one-third required antibiotics. In addition, about 10 percent had some sort of developmental delay and about 20 percent had attention deficit disorder, often due to the lack of an enzyme called adenosine deaminase, one of the causes of SCID. Other conditions appearing in a minority of the patients include diarrhea, rashes and HPV infection. Some of the conditions appeared more frequently in certain SCID subtypes than others.
At least two other centers specializing in SCID have recently published long-term outcome data on their patients, but more of Buckley's patients survived and the survivors are healthier, in general, than their counterparts elsewhere. Buckley, director of Duke's Immune Deficiency Foundation Center of Excellence for Primary Immunodeficiency Diseases and a member of the Institute of Medicine, says the difference may lie in Duke's therapeutic approach.
Unlike other centers, Duke does not use chemotherapy before performing a bone marrow transplant in a SCID infant. "SCID babies do not have any T cells, so they cannot reject a graft. Chemotherapy can harm the lungs, liver and other organs and those who receive it may be sterile as adults."
Even though a tissue-matched related donor - the ideal donor - is rarely available for these infants (only 16 had them in her series), Buckley was able to use half-matched parental donors in the other 145 by using a process to strip away the donor's T cells from the marrow graft to prevent potentially fatal graft-versus-host disease. If T cells are not removed from half-matched marrow, the SCID infant would die of graft-versus-host disease—a reaction of donor T cells against the infant. Removing the T cells from the donor bone marrow also allows omission of immunosuppressive drugs after the transplant, a practice routinely used in many centers. "Giving a SCID infant drugs to suppress the immune system is counterproductive if you are trying to build a new immune system," she says.
In the future, other therapies may be possible. "Gene therapy is likely to be the best option -- if the problems encountered to date can be worked out," says Buckley. Gene therapy trials were halted in 2003 after some patients developed cancer following the therapy, but new trials that may be safer may start soon.
The research was funded by the National Institutes of Allergy, Immunology and Infectious Diseases.
Duke coauthors of the study include Mary D. Railey, M.D. and Yuliya Lokhnygina, Ph.D.
Michelle Gailiun | EurekAlert!
Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
Foods of the future
15.08.2018 | Georg-August-Universität Göttingen
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur
What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...
08.08.2018 | Event News
27.07.2018 | Event News
25.07.2018 | Event News
16.08.2018 | Life Sciences
16.08.2018 | Earth Sciences
16.08.2018 | Life Sciences